University of Alabama at Birmingham

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).

1,160 total trials 216 currently recruiting 723 completed early-phase tilt top decile by trial count

University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.

University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.

Top-decile sponsor footprint

University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 62/100

723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,160 total, page 22 of 24

COMPLETED NA

Dynasplint Therapy for Trismus in Head and Neck Cancer

NCT00507208

COMPLETED

Implantable Antenna Sensors for Continuous Glucose Monitoring

NCT00596323

COMPLETED NA

Nutritional Effect of an Amino Acid Mixture on Lean Body Mass (LBM) in Post-bariatric Surgery Patients

NCT00473356

COMPLETED Phase 1

Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients

NCT00562003

COMPLETED

Inflammatory Cytokine Variations in Traumatic Injury Responses

NCT00593892

COMPLETED Early Phase 1

Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients

NCT00583869

TERMINATED Phase 1

Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates

NCT00599053

COMPLETED NA

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

NCT00476788

COMPLETED NA

Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults

NCT02442479

COMPLETED NA

The Effect of Sedation on Eye Movements

NCT00646646

COMPLETED NA

Intramuscular Lipid and Insulin Action:Ethnic Aspects

NCT00726908

TERMINATED Phase 3

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

NCT00539942

COMPLETED Phase 2

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

NCT00703196

COMPLETED

The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study

NCT00446862

COMPLETED NA

Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery

NCT00473564

COMPLETED

Vitamin D Deficiency in Obese Adolescent Girls and Influence of Vitamin D on Insulin Secretion and Sensitivity

NCT00850694

COMPLETED NA

The Use of RIA to Harvest Bone Graft for Treatment of Non-unions and Fractures

NCT00582439

COMPLETED

A Study to Evaluate Associations Between Gingivitis and Pregnancy Outcomes

NCT00641901

COMPLETED

A Study to Identify Markers in Blood and Tissue of HPV Clearance

NCT00711815

COMPLETED NA

Randomized, Prospective Comparison of Two Femoral Reaming Systems

NCT00594438

TERMINATED Phase 3

Randomized Clinical Trial of Bifocal Lenses Versus Computer-specific Progressive Addition Lenses

NCT00585026

COMPLETED NA

Reading Fluency and Accommodative Lag

NCT00383175

COMPLETED Phase 2

A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma

NCT00369512

COMPLETED Phase 3

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

NCT00294658

COMPLETED Phase 1

An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial; Pilot Study)

NCT00721565

COMPLETED

Genetic and Physical Characteristics of Rett Syndrome

NCT00299312

TERMINATED Phase 2

A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus

NCT00584909

COMPLETED Phase 1

Flavocoxid, A Plant-Derived Therapy, for the Treatment of Knee Osteoarthritis

NCT00294125

COMPLETED NA

Pre-treatment Exercises Versus Post-treatment Exercises for Dysphagia

NCT00584129

COMPLETED Phase 1

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

NCT00584935

TERMINATED NA

Foley Catheter for Labor Induction in Women With Term and Near Term Membrane Rupture

NCT00290199

COMPLETED NA

Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers

NCT00335114

TERMINATED Phase 1

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

NCT00317434

COMPLETED Phase 2

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

NCT00240071

COMPLETED

Determinants of Compliance With Glaucoma Therapy

NCT00362622

COMPLETED Phase 1

Constraint-Induced Therapy Modified for Rehabilitating Arm Function in Stroke Survivors w/Plegic Hands

NCT00366210

COMPLETED Phase 4

The DINE Study-Diet Intervention to Negate Diabetes Study (Improving Weight Loss Outcomes for African Americans)

NCT00599040

COMPLETED Phase 2

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272

TERMINATED Phase 1

Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer

NCT00322920

COMPLETED Phase 2

Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

NCT00161291

COMPLETED Phase 2

Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)

NCT00240097

COMPLETED

Molecular Mechanisms of Mitral Regurgitation-Aim 2

NCT01052532

COMPLETED NA

Internet Intervention to Improve Rural Diabetes Care

NCT00403091

COMPLETED

Evaluation of the ACE Dental Implant

NCT00641576

COMPLETED NA

A Phase II Study of Spinal Radiosurgery

NCT00573872

COMPLETED NA

Effects of Medium Chain Triglyceride Oil, Versus Olive Oil, for Weight Loss

NCT00529919

COMPLETED NA

ADAPT-Altering Diet for African American Populations to Treat Hypertension

NCT00621569

COMPLETED Phase 4

Treatment of Bacterial Vaginosis (BV) With Tinidazole

NCT00334633

COMPLETED NA

Multimodal Physician Intervention to Detect Amblyopia

NCT01109459

COMPLETED Phase 2

Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)

NCT01052428

← Previous Page 22 of 24 Next →

Phase Distribution

PhaseTrial count
Phase 1 129
Phase 2 130
Phase 3 25
Phase 4 72

What is open in the University of Alabama at Birmingham pipeline

216 recruiting of 1,160 indexed (19% open); 723 completed (62%).

Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).

Top condition: Obesity (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Alabama at Birmingham: open-pipeline peers nationwide

Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 15%16%17%18%19% Total trials Recruiting share University of Alabama at BirminghamNYU Langone HealthWake Forest University Health SciencesEmory UniversityNorthwestern UniversityUniversity of MinnesotaMclean HospitalChildren's Hospital Medical Center, CincinnatiArkansas Children's Hospital Research Institute
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,160 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

What to do with this University of Alabama at Birmingham page

1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.

  • 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.